35387-92-9

Usage

InChI:InChI=1/C9H9IO3/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 58123-77-6 3-hydroxy-4-iodobenzoic acid 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 77-78-1 dimethyl sulfate 
• 63435-16-5 3-hydroxy-4-aminobenzoic acid methyl ester 
• 39896-47-4 4-(3'-Methoxyphenyl)-DL-isovalin 
• 39896-53-2 4-(3'-Methoxy-4'-iodphenyl)-DL-isovalin 
• 74-88-4 methyl iodide 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 99-06-9 3-Carboxyphenol 
• 157942-12-6 methyl 3-hydroxy-4-iodobenzoate 
• 39896-41-8 5-(3-methoxy-phenethyl)-5-methyl-imidazolidine-2,4-dione 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 

Downstream Products

• 208399-31-9 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dihydroxy-4-biphenylcarboxamide) 
• 208399-30-8 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dimethoxy-4-biphenylcarboxamide) 
• 282087-44-9 4-iodo-3-(methyloxy)benzoic acid 
• 175152-72-4 methyl 3-methoxy-4-phenylbenzoate 
• 1173176-92-5 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4-iodo-3-methoxyphenyl)ethane-1,2-dione 
• 1231960-83-0 4-iodo-3-methoxy-benzoyl chloride 
• 1368830-73-2 C₁₂H₁₃NO₄ 

Relevant academic research and scientific papers

C3-triiodocyclotriveratrylene as a key intermediate to fluorescent probes: Application to selective choline recognition

A new strategy to obtain fluorescent cyclotriveratrylene (CTV) probes is proposed. The key intermediate, a triiodo CTV, is prepared in 3 steps with 47% overall yield. The whole synthesis requires only one purification step. The potential of this triiodo C

Three sra topological lanthanide-organic frameworks built from 2,2′-dimethoxy-4,4′-biphenyldicarboxylic acid

Three 3D lanthanide-organic frameworks (LOFs), [LnL(HCO2)(DMF)]n (Ln = Eu (1), Gd (2), Dy (3); H2L = 2,2′-dimethoxy-4,4′-biphenyldicarboxylic acid), have been prepared by the solvothermal reaction of Ln(NO3)sub

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

Synthesis of multifunctional metal-organic frameworks and tuning the functionalities with pendant ligands

A series of multifunctional metal-organic frameworks (MOFs), SNU-170-SNU-176, has been synthesized using ligands, in which various functional pendants such as -NH2, -SMe, -OMe, -OEt, -OPr, and -OBu are attached to the phenyl ring of 4-(2-carboxyvinyl)benz

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Total synthesis of polymorphatin A, a macrocyclic bisbibenzyl with boat configured arenes

Polymorphatin A was reported as a constituent of Marchantia polymorpha in 2007 following much speculation as to its likely existence as a natural product. Interest was rekindled when a claimed total synthesis revealed inconsistencies in spectral data betw

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK4 INHIBITORS AND USES THEREOF

Compounds of Formula I as IRAK4 inhibitors are disclosed. The pharmaceutical compositions comprising compounds of formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with IRAK-4 such as inflammatory diseases an